Background Australia has imported IVIg for a number of years to meet the gap between the supply of the domestically produced product (Intragam P) and demand for this product. The outcomes of the recent tender will be effective from 1 January 2012 to 31 December 2014, and may be extended for a further year. Interim arrangements will be in place for the remainder of 2011. The supply arrangements for IVIg from October 2011 are summarised below. What products are available? Funding What indications Who pays for the How are products accessed? arrangement are funded? product? 24 Oct to 31 Dec 2011 From 1 Jan 2012 National Blood Indications funded Intragam P 6% (D) Intragam P 6% (D) Cost is shared between Ordered from and distributed Supply (NBS) under the () the Commonwealth and by the Service. Octagam 5% (I) Octagam 5% # (I) Arrangement the relevant State or Flebogamma 5% DIF (I) Kiovig 10% (I) Territory Jurisdictional For indications that Octagam 5% (I) Octagam 5% # (I) Individual jurisdiction, Ordered from and supplied Direct Order (JDO) are not included hospital, the patient’s directly by the commercial Flebogamma 5% DIF (I) Flebogamma 5% DIF (I) Arrangement under the insurer by special supplier. Kiovig 10% (I) Intragam P cannot be ordered or patient full cost under this arrangement KEY: % = Product Concentration D = Domestic Product I = Imported Product # It is anticipated that a 10% formulation of Octagam will become available under the NBA contract during 2012.
Background Australia has imported IVIg for a number of years to meet the gap between the supply of the domestically produced product (Intragam P) and demand for this product. The outcomes of the recent tender will be effective from 1 January 2012 to 31 December 2014, and may be extended for a further year. Interim arrangements will be in place for the remainder of 2011. The supply arrangements for IVIg from October 2011 are summarised below. Funding arrangement What indications are funded? What products are available? Who pays for the product? How are products accessed? 24 Oct to 31 Dec 2011 From 1 Jan 2012 National Blood Supply (NBS) Arrangement Indications funded under the () Intragam P 6% (D) Octagam 5% (I) Flebogamma 5% DIF (I) Intragam P 6% (D) Octagam 5% # (I) Kiovig 10% (I) Cost is shared between the Commonwealth and the relevant State or Territory Ordered from and distributed by the Service. Jurisdictional Direct Order (JDO) Arrangement For indications that are not included under the Octagam 5% (I) Flebogamma 5% DIF (I) Octagam 5% # (I) Flebogamma 5% DIF (I) Kiovig 10% (I) Individual jurisdiction, hospital, the patient’s insurer by special or patient full cost Ordered from and supplied directly by the commercial supplier. Intragam P cannot be ordered under this arrangement KEY: % = Product Concentration D = Domestic Product I = Imported Product # It is anticipated that a 10% formulation of Octagam will become available under the NBA contract during 2012.
20111019-media-release-imported-ivig_0.docx